Psoriasis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Psoriasis – Pipeline Review, H2 2019’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Psoriasis

– The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects

– The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Psoriasis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“3SBio Inc

AbbVie Inc

Abcentra LLC

AbClon Inc

Abeome Corp

AbGenomics International Inc

Abivax SA

Accuitis Pharmaceuticals Inc

Aclaris Therapeutics Inc

Actinobac Biomed Inc

ActoBio Therapeutics Inc

Aerie Pharmaceuticals Inc

Affibody AB

Affilogic SAS

Agragen LLC

Akeso Biopharma Inc

Alfacyte Ltd

Allianz Pharmascience Ltd

Almirall SA

Aluda Pharmaceuticals Inc

Alvotech ehf

AmDerma Pharmaceuticals LLC

Amgen Inc

AnaptysBio Inc

AntalGenics SL

AnTolRx Inc

Apidel SA

Apimeds Inc

Applied Biology Inc

Arbor Pharmaceuticals LLC

Arcutis Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Athenex Inc

Atlantic Bio Sci LLC

Aurigene Discovery Technologies Ltd

Bayer AG

Beijing Fogangren Bio-Pharm Tech Co Ltd

Beijing Guiqianjin Medical Technology Co Ltd

Beijing Northland Biotech Co Ltd

BioApex sro

Biocon Ltd

BioLingus AG

Biomendics LLC

Biomimetix JV LLC

BioXpress Therapeutics SA

BirchBioMed Inc

Boehringer Ingelheim International GmbH

Boston Pharmaceuticals Inc

Botanix Pharmaceuticals Ltd

Brickell Biotech Inc

Bristol-Myers Squibb Co

c-a-i-r Biosciences GmbH

C4X Discovery Holdings Plc

CalciMedica Inc

Can-Fite BioPharma Ltd

Canvax Biotech SL

Celgene Corp

Celon Pharma SA

CheckPoint Immunology Inc

ChemoCentryx Inc

ChironWells GmbH

Coegin Pharma AS

Coherus BioSciences Inc

Compugen Ltd

Concenter BioPharma Silkim Ltd

Crescita Therapeutics Inc

Curapel Ltd

Cythera Inc

Daiichi Sankyo Co Ltd

Dalriada Therapeutics Inc

Dermavant Sciences Inc

DM Bio Ltd

DNX Biopharmaceuticals Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

DURECT Corp

Eli Lilly and Co

ELORAC Inc

Emeriti Pharma AB

Escalier Biosciences BV

Eternity Bioscience Inc

Evelo Biosciences Inc

Exicure Inc

Fujifilm Kyowa Kirin Biologics Co Ltd

FunPep Co Ltd

FYB202 GmbH & Co KG

Galapagos NV

Galderma SA

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

Genfit SA

Genrix (Shanghai) Biopharmaceutical Co Ltd

GlaxoSmithKline Plc

GlycoMar Ltd

Helix BioMedix Inc

Hengenix Biotech Inc

HitGen LTD

Huabo Biopharm Co Ltd

Hualan Biological Engineering Inc

Hydra Biosciences Inc

Hypo-Stream Ltd

IMGENEX India Pvt Ltd

Immune Pharmaceuticals Inc

Immungenetics AG

Immunic Inc

Immunwork Inc

Innovimmune Biotherapeutics Inc

InSight Biopharmaceuticals Ltd

Inspyr Therapeutics Inc

Instituto Biomar SA

Istesso Ltd

Japan Tobacco Inc

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

JiangSu Qyuns Therapeutics Co Ltd

Johnson & Johnson

JS InnoPharm (Shanghai) Ltd

Jubilant Biosys Ltd

Kadmon Corp LLC

Kaken Pharmaceutical Co Ltd

Kang Stem Biotech Co Ltd

Kangpu Biopharmaceuticals Ltd

Kine Sciences

Krystal Biotech Inc

Kv1.3 Therapeutics

Kymab Ltd

Lead Pharma Holding BV

Leo Pharma AS

Link Health Group

Lipidor AB

Lupin Ltd

Lycera Corp

Machavert Pharmaceuticals LLC

Maruho Co Ltd

Matrisys Bioscience Inc

MC2 Therapeutics AS

Merck KGaA

Metrion Biosciences Ltd

MetrioPharm AG

Mical Pharmaceuticals LLC

Midatech Pharma Plc

Mycenax Biotech Inc

Nektar Therapeutics

Nepsone ehf

Nestle Skin Health SA

NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

NKMAX Co Ltd

Nordic Group BV

NovaLead Pharma Pvt Ltd

Novan Inc

Novartis AG

Numab Innovation AG

Octagon Therapeutics Inc

One World Cannabis Ltd

Orphagen Pharmaceuticals Inc

OSE Immunotherapeutics

P & S Nano Ltd

Palo BioFarma SL

Panaxia Pharmaceutical Industries Ltd

Par’Immune SAS

Pfizer Inc

Pharmapraxis

Philogen SpA

PinCell srl

Pivot Pharmaceuticals Inc

Polpharma Biologics

PRCL Research Inc

Principia Biopharma Inc

Progenra Inc

Promethera Biosciences SA

Provectus Biopharmaceuticals Inc

Pyramid Biosciences Inc

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

Rheos Medicines Inc

Rigel Pharmaceuticals Inc

RNAx Ltd

Samumed LLC

Sareum Holdings Plc

SBI Biotech Co Ltd

selectION Inc

Servatus Ltd

SFA Therapeutics LLC

Shandong Danhong Pharmaceutical Co Ltd

Shanghai Celgen Bio-Pharmaceutical Co Ltd

Shanghai Junshi Bioscience Co Ltd

Shulov Innovative Science Ltd

Siam Bioscience Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sienna Biopharmaceuticals Inc

Singh Biotechnology LLC

Sinocelltech Ltd

Soligenix Inc

Spherium Biomed SL

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

Sunny BioDiscovery Inc

Suzhou Connect Biopharmaceuticals Ltd

Syntrix Biosystems Inc

Taro Pharmaceuticals USA Inc

Temisis Therapeutics

Tianjin Ever Union Biotechnology Co Ltd

Tianjin Hemay Bio-Tech Co Ltd

Tonghua Dongbao Pharmaceutical Co Ltd

UCB SA

V Clinbio LLC

Vidasym Inc

Visionary Pharmaceuticals Inc

Voronoi

vTv Therapeutics Inc

Welichem Biotech Inc

Wellstat Therapeutics Corp

Wuhan Institute of Biological Products Co Ltd

XBiotech Inc

Yuhan Corp

Zai Lab Ltd

Zhejiang Hisun Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Psoriasis Overview 9

Psoriasis Therapeutics Development 10

Psoriasis Therapeutics Assessment 42

Psoriasis Companies Involved in Therapeutics Development 58

Psoriasis Drug Profiles 127

Psoriasis Dormant Projects 660

Psoriasis Discontinued Products 681

Psoriasis Product Development Milestones 685

Appendix 696

List of Tables

“List of Tables

Table 1: Number of Products under Development for Psoriasis, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 10: Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 11: Number of Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 12: Number of Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 13: Number of Products under Development by Universities/Institutes, H2 2019

Table 14: Products under Development by Companies, H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 22: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 23: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 24: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 25: Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Table 26: Products under Development by Companies, H2 2019 (Contd..12), H2 2019

Table 27: Products under Development by Companies, H2 2019 (Contd..13), H2 2019

Table 28: Products under Development by Companies, H2 2019 (Contd..14), H2 2019

Table 29: Products under Development by Companies, H2 2019 (Contd..15), H2 2019

Table 30: Products under Development by Companies, H2 2019 (Contd..16), H2 2019

Table 31: Products under Development by Companies, H2 2019 (Contd..17), H2 2019

Table 32: Products under Development by Universities/Institutes, H2 2019

Table 33: Number of Products by Stage and Target, H2 2019

Table 34: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 35: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 36: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 37: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Table 38: Number of Products by Stage and Mechanism of Action, H2 2019

Table 39: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 40: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 41: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 42: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Table 43: Number of Products by Stage and Route of Administration, H2 2019

Table 44: Number of Products by Stage and Molecule Type, H2 2019

Table 45: Psoriasis – Pipeline by 3SBio Inc, H2 2019

Table 46: Psoriasis – Pipeline by AbbVie Inc, H2 2019

Table 47: Psoriasis – Pipeline by Abcentra LLC, H2 2019

Table 48: Psoriasis – Pipeline by AbClon Inc, H2 2019

Table 49: Psoriasis – Pipeline by Abeome Corp, H2 2019

Table 50: Psoriasis – Pipeline by AbGenomics International Inc, H2 2019

Table 51: Psoriasis – Pipeline by Abivax SA, H2 2019

Table 52: Psoriasis – Pipeline by Accuitis Pharmaceuticals Inc, H2 2019

Table 53: Psoriasis – Pipeline by Aclaris Therapeutics Inc, H2 2019

Table 54: Psoriasis – Pipeline by Actinobac Biomed Inc, H2 2019

Table 55: Psoriasis – Pipeline by ActoBio Therapeutics Inc, H2 2019

Table 56: Psoriasis – Pipeline by Aerie Pharmaceuticals Inc, H2 2019

Table 57: Psoriasis – Pipeline by Affibody AB, H2 2019

Table 58: Psoriasis – Pipeline by Affilogic SAS, H2 2019

Table 59: Psoriasis – Pipeline by Agragen LLC, H2 2019

Table 60: Psoriasis – Pipeline by Akeso Biopharma Inc, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Psoriasis, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports